冠状动脉支架植入时开始使用阿托伐他汀（80毫克）对C反应蛋白及六个月临床事件的影响。 - Suppr

Suppr

超能文献

Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events.

作者信息

Gaspardone Achille, Versaci Francesco, Proietti Igino, Tomai Fabrizio, Altamura Luca, Skossyreva Olga, Chiariello Luigi

机构信息

Cattedra di Cardiochirurgia, Università Tor Vergata, Rome, Italy.

出版信息

Am J Cardiol. 2002 Oct 1;90(7):786-9. doi: 10.1016/s0002-9149(02)02615-2.

DOI:10.1016/s0002-9149(02)02615-2

PMID:12356402

Abstract

摘要

相似文献

Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events.冠状动脉支架植入时开始使用阿托伐他汀（80毫克）对C反应蛋白及六个月临床事件的影响。

Am J Cardiol. 2002 Oct 1;90(7):786-9. doi: 10.1016/s0002-9149(02)02615-2.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.10毫克与80毫克阿托伐他汀对稳定型冠状动脉疾病患者高敏C反应蛋白的比较效应：CAP（阿托伐他汀多效性比较）研究结果

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

Am J Cardiol. 2005 Jan 15;95(2):249-53. doi: 10.1016/j.amjcard.2004.09.012.

Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia.大剂量阿托伐他汀治疗家族性高胆固醇血症患者的长期安全性和疗效。

Am J Cardiol. 2005 Jan 15;95(2):264-6. doi: 10.1016/j.amjcard.2004.09.015.

[Results of randomized study: intensive lipid lowering treatment stops coronary atherosclerosis].[随机研究结果：强化降脂治疗可阻止冠状动脉粥样硬化]

MMW Fortschr Med. 2004 Mar 25;146(13):64-5.

Efficacy of atorvastatin in primary hypercholesterolemia. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group.阿托伐他汀治疗原发性高胆固醇血症的疗效。日本降胆固醇阿托伐他汀研究（J-CLAS）组。

Am J Cardiol. 1997 May 1;79(9):1248-52.

Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.不同冠心病风险患者隔日阿托伐他汀治疗与每日治疗维持 LDL-胆固醇靶目标的比较。

J Cardiovasc Pharmacol. 2012 May;59(5):479-84. doi: 10.1097/FJC.0b013e31824ba699.

A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg.一项多中心、八周治疗、单步滴定、开放性研究，评估起始剂量为 10mg、20mg 和 40mg 的阿托伐他汀使韩国血脂异常患者达到 LDL 胆固醇目标的百分比。

Cardiovasc Drugs Ther. 2010 Apr;24(2):181-8. doi: 10.1007/s10557-010-6225-0.

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.强化降脂治疗与中度降脂治疗对冠状动脉粥样硬化进展的影响：一项随机对照试验。

JAMA. 2004 Mar 3;291(9):1071-80. doi: 10.1001/jama.291.9.1071.

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.依折麦布与阿托伐他汀联合应用于628例原发性高胆固醇血症患者的疗效：一项前瞻性、随机、双盲试验。

Circulation. 2003 May 20;107(19):2409-15. doi: 10.1161/01.CIR.0000068312.21969.C8. Epub 2003 Apr 28.

引用本文的文献

Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes.经皮冠状动脉介入治疗与急性冠状动脉综合征患者长期 C 反应蛋白水平的关系。

J Thromb Thrombolysis. 2010 Jul;30(1):10-3. doi: 10.1007/s11239-010-0463-7.

Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.阿托伐他汀在心血管事件一级和二级预防中的疗效。

Drugs. 2007;67 Suppl 1:29-42. doi: 10.2165/00003495-200767001-00004.

A comparison of coronary artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery: five year clinical follow up.冠状动脉左前降支近端孤立性狭窄的冠状动脉支架置入术与血管成形术比较：五年临床随访

Heart. 2004 Jun;90(6):672-5. doi: 10.1136/hrt.2003.020826.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验